Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Urologic oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2015.08.005PMID 26362343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2015

  2015cited by this paper
• Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.

  2015cited by this paper
• Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base.

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Comprehensive molecular characterization of urothelial bladder carcinoma

  2014cited by this paper
• The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder

  2012cited by this paper
• Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer.

  2011cited by this paper
• Curcumin Modulates MicroRNA-203–Mediated Regulation of the Src-Akt Axis in Bladder Cancer

  2011cited by this paper
• International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

  2011cited by this paper
• Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling

  2010cited by this paper
• Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline.

  2010cited by this paper
• Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.

  2009cited by this paper
• Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

  2009cited by this paper
• Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function

  2009cited by this paper
• Outcome after radical cystectomy with limited or extended pelvic lymph node dissection.

  2008cited by this paper
• Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

  2007cited by this paper
• Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

  2007cited by this paper
• Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

  2007cited by this paper
• Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder

  2006cited by this paper
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

  2005cited by this paper
• Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

  2005cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Src kinase contributes to the metastatic spread of carcinoma cells

  2002cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Elevated c-Src protein expression is an early event in colonic neoplasia.

  1998cited by this paper
• Elevated expression of pp60c-src in low grade human bladder carcinoma.

  1992cited by this paper

• Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta‐analysis

  2025cites this paper
• Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer

  2024cites this paper
• Dasatinib induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells

  2024cites this paper
• Prognostic analysis of anoikis-related genes in bladder cancer: An observational study

  2024cites this paper
• Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma

  2024cites this paper
• Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of bladder cancer cells through its hem‐immunoreceptor tyrosine‐based activation motif

  2024cites this paper
• mRNA–miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis

  2022cites this paper
• Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review

  2022cites this paper
• Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations

  2020cites this paper
• Targeting the Src pathway enhances the efficacy of selective FGFR inhibitors in cancers with FGFR3 alterations

  2020cites this paper
• Neoadjuvant therapy for muscle-invasive bladder cancer

  2020cites this paper
• Organoid model of urothelial cancer: establishment and applications for bladder cancer research.

  2020cites this paper
• Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer.

  2017cites this paper
• Contemporary update on neoadjuvant therapy for bladder cancer

  2017cites this paper
• The Neoadjuvant Paradigm for Development of Systemic Therapy and Precision Medicine for Bladder Cancer.

  2016cites this paper
• Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer.

  2016cites this paper
• Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET

  2016cites this paper
• Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion

  2016cites this paper
• Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

  2016cites this paper
• Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?

  2016cites this paper
• [Update on molecular classifications and new histological classification of bladder cancer].

  2016cites this paper